SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of PetMed Express, Inc.

NEW YORK, June 15, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors in PetMed Express, Inc. (“PetMed” or the “Company”) (NASDAQ: PETS). Such investors are advised to contact Danielle Peyton at (email protected) or 646-581-9980, extension 7980.

The investigation concerns whether PetMed and certain of its officers and/or directors engaged in securities transactions. Fraud or other unlawful business practices.

(Click here for information on joining the class action lawsuit.)

At June 11, 2024PetMed released a press release announcing its financial results for the fourth quarter and fiscal year 2024. Among other things, PetMed reported a net loss per share of 0.25 USDcompared to a net loss per share of 0.01 USD in the same period last year. Although PetMed reported an increase in net sales compared to the prior year, this was offset by an increase in total operating expenses. PetMed had approximately 55.3 million US dollars in cash at the end of fiscal year 2024, compared to approx. 104.1 million US dollars at the end of the 2023 financial year.

Following this news, PetMed’s share price fell $0.54 per share or 11.46% and closed at $4.17 per share on June 12, 2024.

Pomerantz LLP, with offices in new York, Chicago, Los Angeles, London, ParisAnd Tel-Avivis considered one of the leading law firms in the areas of corporate, securities and antitrust litigation. Founded by the late Abraham L. PomerantzKnown as the dean of class action lawyers, Pomerantz was a pioneer in the field of securities class action litigation. Today, more than 85 years later, Pomerantz continues the tradition he established and fights for the rights of securities litigation victims. FraudBreach of fiduciary duty and corporate misconduct. The firm has won billions of dollars in damages on behalf of class action plaintiffs. See www.pomlaw.com.

Attorney advertising. Past results do not guarantee similar results.

CONTACT:
Danielle Peyton
Pomerantz LLP
(email protected)
646-581-9980 extension 7980

Never miss a story from Pomerantz LLP again.